Novartis: latest news - GoINPHARMA
Monday, 24 September 2018 - 1:29

Novartis

Novartis sells US dermatology unit to Aurobindo for 1 billion dollars

Switzerland-based Novartis yesterday evening announced that it has sold its US dermatology unit to Aurobindo Pharma for $900m. The deal includes an additional payment of $100m of potential earn-outs, based on successful completion of precise milestones. The divested unit is…

Everything in place for launch of Novartis’ Kymriah in UK

The UK National Health Service and Novartis yesterday announced they have entered into an agreement to commercialize the immunotherapy Kymriah (tisagenlecleucel) for patients with a rare type of leukemia (ALL) in the UK, but they have not disclosed the price…

Good Phase III results for Novartis’ cancer drug (breast cancer)

Novartis has announced today that its investigational BYL719  (alpelisib) therapy has reached its primary endpoints in the Phase III Solar-1 clinical trial. BYL719 is an alpha-specific PI3K inhibitor developed for the treatment of PIK3CA-mutant breast cancer, tested as intravenous infusion…

Novartis’ pipeline

Paul Hudson, head of Novartis group’s pharmaceutical division, has given a long interview to the weekly Finanz und Wirtschaft today. The main topic has been the controversial issue of  drug prices and, specifically, Trump administration’s request to pharmaceutical companies to…

Novartis pays $1bn for Galapagos’ atopic dermatitis therapy

Novartis has announced it has acquired the rights to an atopic dermatitis treatment from Belgium-based Galapagos and Germany-based MorphoSys. The treatment, named MOR106, is a monoclonal antibody still undergoing clinical trials–a Phase II study was started in May 2018, but…

Moody’s downgrades Novartis’ rating

Last week Novartis announced it was willing to spin off its Alcon unit to create a new independent business worth around $20bn. The idea was positively welcomed by the stock exchange, with shares rising 4%. However, to everyone’s astonishment, credit…

Novartis signed deal with Adamis to gun for Mylan EpiPen’s market

Novartis was granted via subsidiary company Sandoz the U.S. commercial rights for Symjepi, an allergic reaction treatment developed by Adamis Pharmaceuticals. As a matter of fact, Symjepi is a prefilled epinephrine syringe, that is the same active substance as Mylan’s…

NTC acquires part of Novartis’ ophthalmic portfolio

Italy-based pharmaceutical group NTC has acquired part of Novartis’ ophthalmic portfolio for the Spanish, Portuguese, Italian and Polish markets. The acquired products include  Colircusi Gentadexa (aminoglycoside), Colircusi Gentamicin and Oftalmolosa Cusi Gentamicina (aminoglycoside), Oftalmolosa Cusi Erythromycin (macrolide), Oftalmolosa Cusi Aureomycin…

List of likely buyers of Novartis’ Dermatology division ($2bn) takes shape

A list of likely buyers of Novartis’ US dermatology generics division, valued at an approximate $2bn, is now drawn up, Bloomberg has reported. The list includes China-based Shanghai Fosun Pharmaceutical, Apollo Global Management, CVC Capital Partners and India-based Aurobindo Pharma. …

FDA approves Tafinlar + Mekinist combo for thyroid cancer

The FDA has approved the Tafinlar (dabrafenib) + Mekinist (trametinib) combo, by Switzerland-based Novartis, for patients with anaplastic thyroid cancer that cannot be removed by surgery. This is the first therapy approved by FDA for patients with this thyroid cancer…

Aurobindo offers $1.6bn for Sandoz-Novartis’ dermatology (generics) division

India-based Aurobindo Pharma (Hyderabad) has offered $1.6bn for Sandoz’s unit manufacturing and marketing dermatology generics. Other investors are targeting Sandoz’s asset, including pharmaceutical companies and private equities, Livemint has reported. The deadline set by Sandoz to submit offers is June…

Neue Entwicklungen der Membrantechnologie zur Wasserentsalzung

Ein Forscherteam der Zhejiang University von Hangzhou in China hat in der berühmten Zeitschrift Science die Synthese neuer Nanomembranen für die Wasserentsalzung gezeigt. Die neue Membran hat eine Struktur, die eine bessere Separierung großer Ionen ermöglicht und wird durch die…

First quarter meeting expectations for Novartis

Switzerland-based pharmaceutical group Novartis has announced today its Q1 2018 results. These have not satisfied investors, indeed Novartis’ shares have lost almost 3% (Zurich). The group’s profits have increased by 22% ($2.03bn), especially thanks to products against cancer and cardiovascular…

New deal for Novartis

It is widely understood that new Novartis CEO Vas Narasimhan has a far more aggressive managerial style than his predecessor Joseph Jiménez. Since Narasimhan was appointed CEO, Novartis has entered into M&A agreements for a total of $25.8bn: it has…

Novartis acquires AveXis for $8.7bn

Novartis has announced it has acquired AveXis for $8.7bn, paying it $218 per share, that is a 88% premium over the company’s closing price on Friday ($115.9). AveXis focuses on gene therapies for the treatment of spinal muscular atrophy and…

Novartis sells GSK its share in JV Consumer Health for $13bn

Novartis and GlaxoSmithKline have jointly announced today, before trading opened in Europe, that GSK has sold 36.5% of JV Consumer Health’s shares to GSK for $13bn. The deal allows GSK to secure one of the largest Consumer Health divisions in…

Top management revolution at Novartis

The new Novartis CEO Vas Narasimhan is revolutionizing his management team, as many people expected. The veteran Wyss Andre, 51, head of Novartis Switzerland for years now, will leave his office and will be replaced by another veteran in Novartis’…

Vasant Narasimhan, Novartis CEO, describes group’s R&D strategy

41-year-old Novartis new CEO Vasant Narasimhan has announced his R&D strategy for the Basel-based group. Narasimhan is seeking to innovate the data science and digital technologies divisions, which he expects to be the development drivers for new drugs. Additionally, the…

Novartis starts divesting Sandoz’s North-American business ($1.6bn)

Reuters yesterday announced that Switzerland-based Novartis has started the process to divest the North-American division of Sandoz, its generic pills business. The divestiture may attract other drugmakers and private equities, ready to offer a minimum of $1.6bn, that is 8x…

Joe Jiménez, Novartis outgoing CEO, describes group’s strategy

The German daily Neue Zürcher Zeitung has published a long interview to Joe Jiménez, outgoing CEO of Switzerland-based pharmaceutical group Novartis. The American manager has addressed the ethical value of drug manufacturing and marketing and the need to make them…

Here is the salary of new Novartis CEO Vas Narasimhan

The salary of the new Novartis CEO Vas Narasimhan is fairly below that of his predecessor Joe Jiménez. The outgoing CEO in 2017 earned CHF13.1m, whereas his successor will earn an estimated CHF8.9m, subject to fulfillment of all the set…

Novartis to pay $170m for Spark Therapeutics’ gene therapy

Novartis’ new CEO Vas Narasimhan appears to be fulfilling the promises made when he was appointed, as he announced he was determined to invest on gene therapies. Novartis announced yesterday night that it has acquired the commercialization rights outside the…

Sandoz (Novartis) and Biocon announce cooperation agreement over biosimilars

Sandoz–subsidiary of Novartis’–and India-based Biocon have announced a cooperation agreement aimed at manufacturing and marketing new biosimilars for immunology and oncology. Under the terms of the agreement, Sandoz will obtain commercialization rights to novel biosimilars for NAFTA and most of…